PMC:7296049 / 25227-26349 JSONTXT

{"target":"http://pubannotation.org/docs/sourcedb/PMC/sourceid/7296049","sourcedb":"PMC","sourceid":"7296049","source_url":"https://www.ncbi.nlm.nih.gov/pmc/7296049","text":"Figure 4 Dl-3-n-butylphthalide (NBP) promotes oligodendrocytes regeneration in corpus callosum after 2VO. (A) Representative images of Olig2 (red) and BrdU (green) immunofluorescence double labeling in corpus callosum at 2 weeks and 4 weeks after 2VO. Bar = 50 μm. Typical double-labeled areas are magnified (n = 3 in each group). (B) Western blot analysis of the expressions of Olig2 (n = 6 in each group). (C) The number of Olig2+ cells in corpus callosum. (D) The number of Olig2+/BrdU+ cells in corpus callosum. (E) Quantitative analysis of protein levels of Olig2. β-actin was used as an internal control. (F) Quantitative analysis of mRNA levels of Olig2. β-actin was used as an internal control (n = 6 in each group). **p \u003c 0.01, ***p \u003c 0.001, the model group vs. the sham group; #p \u003c 0.05, ##p \u003c 0.01, ###p \u003c 0.001, the NBP60 group or NBP120 group vs. the model group; $p \u003c 0.05, $$$p \u003c 0.001, the NBP60 group vs. NBP120 group; and \u0026p \u003c 0.05, the model group sacrificed at 2 weeks vs. the model group sacrificed at 4 weeks. Values are expressed as mean ± SD. Olig2, oligodendrocyte lineage transcription factor 2.","divisions":[{"label":"label","span":{"begin":0,"end":8}}],"tracks":[]}